{"id":32295,"date":"2025-07-30T08:40:38","date_gmt":"2025-07-30T08:40:38","guid":{"rendered":"https:\/\/ibima.eu\/ensayo-fase-iii-aleatorizado-doble-ciego-controlado-con-placebo-multicentrico-del-inhibidor-pi3k-intravenoso-copanlisib-en-combinacion-con-inmunoquimioterapia-estandar-versus-inmunoquimioterapia-e\/"},"modified":"2025-07-30T08:40:38","modified_gmt":"2025-07-30T08:40:38","slug":"ensayo-fase-iii-aleatorizado-doble-ciego-controlado-con-placebo-multicentrico-del-inhibidor-pi3k-intravenoso-copanlisib-en-combinacion-con-inmunoquimioterapia-estandar-versus-inmunoquimioterapia-e","status":"publish","type":"post","link":"https:\/\/ibima.eu\/es\/ensayo-fase-iii-aleatorizado-doble-ciego-controlado-con-placebo-multicentrico-del-inhibidor-pi3k-intravenoso-copanlisib-en-combinacion-con-inmunoquimioterapia-estandar-versus-inmunoquimioterapia-e\/","title":{"rendered":"Ensayo fase III, aleatorizado, doble ciego, controlado con placebo, multic\u00e9ntrico del inhibidor PI3K intravenoso Copanlisib en combinaci\u00f3n con inmunoquimioterapia est\u00e1ndar versus inmunoquimioterapia est\u00e1ndar en pacientes con linfoma no Hodgkin indolente tras reca\u00edda"},"content":{"rendered":"

MANUEL ESPESO DE HARO – ENSAYO CLINICO COMERCIAL – III – BAYER AG<\/p>\n","protected":false},"excerpt":{"rendered":"

MANUEL ESPESO DE HARO – ENSAYO CLINICO COMERCIAL – III – BAYER AG<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[2263,2901],"tags":[],"class_list":["post-32295","post","type-post","status-publish","format-standard","hentry","category-ensayos-clinicos","category-ensayos-clinicos-be-03"],"acf":[],"yoast_head":"\nEnsayo fase III, aleatorizado, doble ciego, controlado con placebo, multic\u00e9ntrico del inhibidor PI3K intravenoso Copanlisib en combinaci\u00f3n con inmunoquimioterapia est\u00e1ndar versus inmunoquimioterapia est\u00e1ndar en pacientes con linfoma no Hodgkin indolente tras reca\u00edda - Ibima<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ibima.eu\/es\/ensayo-fase-iii-aleatorizado-doble-ciego-controlado-con-placebo-multicentrico-del-inhibidor-pi3k-intravenoso-copanlisib-en-combinacion-con-inmunoquimioterapia-estandar-versus-inmunoquimioterapia-e\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ensayo fase III, aleatorizado, doble ciego, controlado con placebo, multic\u00e9ntrico del inhibidor PI3K intravenoso Copanlisib en combinaci\u00f3n con inmunoquimioterapia est\u00e1ndar versus inmunoquimioterapia est\u00e1ndar en pacientes con linfoma no Hodgkin indolente tras reca\u00edda - Ibima\" \/>\n<meta property=\"og:description\" content=\"MANUEL ESPESO DE HARO – ENSAYO CLINICO COMERCIAL – III – BAYER AG\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ibima.eu\/es\/ensayo-fase-iii-aleatorizado-doble-ciego-controlado-con-placebo-multicentrico-del-inhibidor-pi3k-intravenoso-copanlisib-en-combinacion-con-inmunoquimioterapia-estandar-versus-inmunoquimioterapia-e\/\" \/>\n<meta property=\"og:site_name\" content=\"Ibima\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-30T08:40:38+00:00\" \/>\n<meta name=\"author\" content=\"prodriguez\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"prodriguez\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/ensayo-fase-iii-aleatorizado-doble-ciego-controlado-con-placebo-multicentrico-del-inhibidor-pi3k-intravenoso-copanlisib-en-combinacion-con-inmunoquimioterapia-estandar-versus-inmunoquimioterapia-e\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/ensayo-fase-iii-aleatorizado-doble-ciego-controlado-con-placebo-multicentrico-del-inhibidor-pi3k-intravenoso-copanlisib-en-combinacion-con-inmunoquimioterapia-estandar-versus-inmunoquimioterapia-e\\\/\"},\"author\":{\"name\":\"prodriguez\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#\\\/schema\\\/person\\\/40b410344dd5ad2315bb651e3fbfa635\"},\"headline\":\"Ensayo fase III, aleatorizado, doble ciego, controlado con placebo, multic\u00e9ntrico del inhibidor PI3K intravenoso Copanlisib en combinaci\u00f3n con inmunoquimioterapia est\u00e1ndar versus inmunoquimioterapia est\u00e1ndar en pacientes con linfoma no Hodgkin indolente tras reca\u00edda\",\"datePublished\":\"2025-07-30T08:40:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/ensayo-fase-iii-aleatorizado-doble-ciego-controlado-con-placebo-multicentrico-del-inhibidor-pi3k-intravenoso-copanlisib-en-combinacion-con-inmunoquimioterapia-estandar-versus-inmunoquimioterapia-e\\\/\"},\"wordCount\":51,\"commentCount\":0,\"articleSection\":[\"Ensayos Cl\u00ednicos\",\"Ensayos Cl\u00ednicos - BE-03\"],\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/ibima.eu\\\/ensayo-fase-iii-aleatorizado-doble-ciego-controlado-con-placebo-multicentrico-del-inhibidor-pi3k-intravenoso-copanlisib-en-combinacion-con-inmunoquimioterapia-estandar-versus-inmunoquimioterapia-e\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/ensayo-fase-iii-aleatorizado-doble-ciego-controlado-con-placebo-multicentrico-del-inhibidor-pi3k-intravenoso-copanlisib-en-combinacion-con-inmunoquimioterapia-estandar-versus-inmunoquimioterapia-e\\\/\",\"url\":\"https:\\\/\\\/ibima.eu\\\/ensayo-fase-iii-aleatorizado-doble-ciego-controlado-con-placebo-multicentrico-del-inhibidor-pi3k-intravenoso-copanlisib-en-combinacion-con-inmunoquimioterapia-estandar-versus-inmunoquimioterapia-e\\\/\",\"name\":\"Ensayo fase III, aleatorizado, doble ciego, controlado con placebo, multic\u00e9ntrico del inhibidor PI3K intravenoso Copanlisib en combinaci\u00f3n con inmunoquimioterapia est\u00e1ndar versus inmunoquimioterapia est\u00e1ndar en pacientes con linfoma no Hodgkin indolente tras reca\u00edda - Ibima\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#website\"},\"datePublished\":\"2025-07-30T08:40:38+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#\\\/schema\\\/person\\\/40b410344dd5ad2315bb651e3fbfa635\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/ensayo-fase-iii-aleatorizado-doble-ciego-controlado-con-placebo-multicentrico-del-inhibidor-pi3k-intravenoso-copanlisib-en-combinacion-con-inmunoquimioterapia-estandar-versus-inmunoquimioterapia-e\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ibima.eu\\\/ensayo-fase-iii-aleatorizado-doble-ciego-controlado-con-placebo-multicentrico-del-inhibidor-pi3k-intravenoso-copanlisib-en-combinacion-con-inmunoquimioterapia-estandar-versus-inmunoquimioterapia-e\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/ensayo-fase-iii-aleatorizado-doble-ciego-controlado-con-placebo-multicentrico-del-inhibidor-pi3k-intravenoso-copanlisib-en-combinacion-con-inmunoquimioterapia-estandar-versus-inmunoquimioterapia-e\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\\\/\\\/ibima.eu\\\/es\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ensayo fase III, aleatorizado, doble ciego, controlado con placebo, multic\u00e9ntrico del inhibidor PI3K intravenoso Copanlisib en combinaci\u00f3n con inmunoquimioterapia est\u00e1ndar versus inmunoquimioterapia est\u00e1ndar en pacientes con linfoma no Hodgkin indolente tras reca\u00edda\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/ibima.eu\\\/es\\\/\",\"name\":\"Ibima\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ibima.eu\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#\\\/schema\\\/person\\\/40b410344dd5ad2315bb651e3fbfa635\",\"name\":\"prodriguez\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g\",\"caption\":\"prodriguez\"},\"sameAs\":[\"https:\\\/\\\/ibima.eu\"],\"url\":\"https:\\\/\\\/ibima.eu\\\/es\\\/author\\\/prodriguez\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ensayo fase III, aleatorizado, doble ciego, controlado con placebo, multic\u00e9ntrico del inhibidor PI3K intravenoso Copanlisib en combinaci\u00f3n con inmunoquimioterapia est\u00e1ndar versus inmunoquimioterapia est\u00e1ndar en pacientes con linfoma no Hodgkin indolente tras reca\u00edda - Ibima","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ibima.eu\/es\/ensayo-fase-iii-aleatorizado-doble-ciego-controlado-con-placebo-multicentrico-del-inhibidor-pi3k-intravenoso-copanlisib-en-combinacion-con-inmunoquimioterapia-estandar-versus-inmunoquimioterapia-e\/","og_locale":"es_ES","og_type":"article","og_title":"Ensayo fase III, aleatorizado, doble ciego, controlado con placebo, multic\u00e9ntrico del inhibidor PI3K intravenoso Copanlisib en combinaci\u00f3n con inmunoquimioterapia est\u00e1ndar versus inmunoquimioterapia est\u00e1ndar en pacientes con linfoma no Hodgkin indolente tras reca\u00edda - Ibima","og_description":"MANUEL ESPESO DE HARO – ENSAYO CLINICO COMERCIAL – III – BAYER AG","og_url":"https:\/\/ibima.eu\/es\/ensayo-fase-iii-aleatorizado-doble-ciego-controlado-con-placebo-multicentrico-del-inhibidor-pi3k-intravenoso-copanlisib-en-combinacion-con-inmunoquimioterapia-estandar-versus-inmunoquimioterapia-e\/","og_site_name":"Ibima","article_published_time":"2025-07-30T08:40:38+00:00","author":"prodriguez","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"prodriguez"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ibima.eu\/ensayo-fase-iii-aleatorizado-doble-ciego-controlado-con-placebo-multicentrico-del-inhibidor-pi3k-intravenoso-copanlisib-en-combinacion-con-inmunoquimioterapia-estandar-versus-inmunoquimioterapia-e\/#article","isPartOf":{"@id":"https:\/\/ibima.eu\/ensayo-fase-iii-aleatorizado-doble-ciego-controlado-con-placebo-multicentrico-del-inhibidor-pi3k-intravenoso-copanlisib-en-combinacion-con-inmunoquimioterapia-estandar-versus-inmunoquimioterapia-e\/"},"author":{"name":"prodriguez","@id":"https:\/\/ibima.eu\/es\/#\/schema\/person\/40b410344dd5ad2315bb651e3fbfa635"},"headline":"Ensayo fase III, aleatorizado, doble ciego, controlado con placebo, multic\u00e9ntrico del inhibidor PI3K intravenoso Copanlisib en combinaci\u00f3n con inmunoquimioterapia est\u00e1ndar versus inmunoquimioterapia est\u00e1ndar en pacientes con linfoma no Hodgkin indolente tras reca\u00edda","datePublished":"2025-07-30T08:40:38+00:00","mainEntityOfPage":{"@id":"https:\/\/ibima.eu\/ensayo-fase-iii-aleatorizado-doble-ciego-controlado-con-placebo-multicentrico-del-inhibidor-pi3k-intravenoso-copanlisib-en-combinacion-con-inmunoquimioterapia-estandar-versus-inmunoquimioterapia-e\/"},"wordCount":51,"commentCount":0,"articleSection":["Ensayos Cl\u00ednicos","Ensayos Cl\u00ednicos - BE-03"],"inLanguage":"es","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ibima.eu\/ensayo-fase-iii-aleatorizado-doble-ciego-controlado-con-placebo-multicentrico-del-inhibidor-pi3k-intravenoso-copanlisib-en-combinacion-con-inmunoquimioterapia-estandar-versus-inmunoquimioterapia-e\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ibima.eu\/ensayo-fase-iii-aleatorizado-doble-ciego-controlado-con-placebo-multicentrico-del-inhibidor-pi3k-intravenoso-copanlisib-en-combinacion-con-inmunoquimioterapia-estandar-versus-inmunoquimioterapia-e\/","url":"https:\/\/ibima.eu\/ensayo-fase-iii-aleatorizado-doble-ciego-controlado-con-placebo-multicentrico-del-inhibidor-pi3k-intravenoso-copanlisib-en-combinacion-con-inmunoquimioterapia-estandar-versus-inmunoquimioterapia-e\/","name":"Ensayo fase III, aleatorizado, doble ciego, controlado con placebo, multic\u00e9ntrico del inhibidor PI3K intravenoso Copanlisib en combinaci\u00f3n con inmunoquimioterapia est\u00e1ndar versus inmunoquimioterapia est\u00e1ndar en pacientes con linfoma no Hodgkin indolente tras reca\u00edda - Ibima","isPartOf":{"@id":"https:\/\/ibima.eu\/es\/#website"},"datePublished":"2025-07-30T08:40:38+00:00","author":{"@id":"https:\/\/ibima.eu\/es\/#\/schema\/person\/40b410344dd5ad2315bb651e3fbfa635"},"breadcrumb":{"@id":"https:\/\/ibima.eu\/ensayo-fase-iii-aleatorizado-doble-ciego-controlado-con-placebo-multicentrico-del-inhibidor-pi3k-intravenoso-copanlisib-en-combinacion-con-inmunoquimioterapia-estandar-versus-inmunoquimioterapia-e\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ibima.eu\/ensayo-fase-iii-aleatorizado-doble-ciego-controlado-con-placebo-multicentrico-del-inhibidor-pi3k-intravenoso-copanlisib-en-combinacion-con-inmunoquimioterapia-estandar-versus-inmunoquimioterapia-e\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/ibima.eu\/ensayo-fase-iii-aleatorizado-doble-ciego-controlado-con-placebo-multicentrico-del-inhibidor-pi3k-intravenoso-copanlisib-en-combinacion-con-inmunoquimioterapia-estandar-versus-inmunoquimioterapia-e\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/ibima.eu\/es\/"},{"@type":"ListItem","position":2,"name":"Ensayo fase III, aleatorizado, doble ciego, controlado con placebo, multic\u00e9ntrico del inhibidor PI3K intravenoso Copanlisib en combinaci\u00f3n con inmunoquimioterapia est\u00e1ndar versus inmunoquimioterapia est\u00e1ndar en pacientes con linfoma no Hodgkin indolente tras reca\u00edda"}]},{"@type":"WebSite","@id":"https:\/\/ibima.eu\/es\/#website","url":"https:\/\/ibima.eu\/es\/","name":"Ibima","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ibima.eu\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Person","@id":"https:\/\/ibima.eu\/es\/#\/schema\/person\/40b410344dd5ad2315bb651e3fbfa635","name":"prodriguez","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/secure.gravatar.com\/avatar\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g","caption":"prodriguez"},"sameAs":["https:\/\/ibima.eu"],"url":"https:\/\/ibima.eu\/es\/author\/prodriguez\/"}]}},"_links":{"self":[{"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/posts\/32295","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/comments?post=32295"}],"version-history":[{"count":3,"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/posts\/32295\/revisions"}],"predecessor-version":[{"id":55307,"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/posts\/32295\/revisions\/55307"}],"wp:attachment":[{"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/media?parent=32295"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/categories?post=32295"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/tags?post=32295"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}